Entecavir Plus Adefovir in Lamivudine-Resistant Chronic Hepatitis B Patients Who Fail Lamivudine Plus Adefovir

Hepatitis B, Chronic Clinical Trial

— CAESAR  

Official title:

Continuation of Lamivudine Plus Adefovir Versus Switching to Entecavir Plus Adefovir in Adults With Chronic Hepatitis B Who Have Resistant Mutants to Lamivudine and Show Suboptimal Response to Combination of Lamivudine Plus Adefovir

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01023217
• Other study ID #: AMC-2009-0536
• Status: Completed
• Phase: Phase 4
• First received: December 1, 2009
• Last updated: January 15, 2014
• Start date: November 2009
• Est. completion date: September 2012

Study information

• Verified date: January 2014
• Source: Asan Medical Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: South Korea: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The presence of persistent inadequate or suboptimal virologic response is a strong risk factor for viral resistance and breakthrough and also for disease progression of chronic hepatitis B, and thus, a change in therapy is required. The combination of entecavir (ETV) and adefovir (ADV) is a promising treatment for patients with lamivudine (LAM)-resistance who show suboptimal response to the combination of LAM and ADV.

In this randomized, open labeled trial,the investigators will compare the efficacy of continuation of ADV plus LAM versus switch to ADV plus ETV in adults with LAM-resistant chronic hepatitis B who shows suboptimal response to the combination treatment of ADV and LAM.

Description:

In this randomized, open label, two-arm, single center phase IV trial, the investigators will assess and compare the efficacy and safety of continuation of ADV plus LAM versus switching to ADV plus ETV up to 52-weeks in Korean adults with chronic hepatitis B who have resistant mutants to LAM and show suboptimal response to combination of ADV plus LAM.

All study subjects who complete the initial treatments of 52-weeks will be thereafter treated with the combination of ADV plus ETV for 52 more weeks.

Study period: Nov 2009 - October 2012 Patient enrollment period: November 2009 - December 2010

Study protocol

1. Group A (ADV+LAM group): Adefovir (10 mg/day) + Lamivudine (100 mg/day) for 52 weeks, and thereafter, Adefovir (10 mg/day) + Entecavir (1 mg/day) for 52 more weeks

2. Group B (ADV+ETV group): Adefovir (10 mg/day) + Entecavir (1 mg/day) for 104 weeks

Recruitment information / eligibility

• Status: Completed
• Enrollment: 90
• Est. completion date: September 2012
• Est. primary completion date: July 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 16 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Male or female, 16 to 75 years of age

2. Compensated liver disease(Child-Pugh class A)

3. HBsAg positive at least 6 months or more

4. HBeAg positive or negative

5. Confirmation of Lamivudine-resistance HBV mutation anytime before the study

6. Patients with suboptimal response (HBV DNA > 2000 IU/mL despite combination of Adefovir [10 mg/day] plus Lamivudine [100 mg/day] for 6 months or more). Serum HBV DNA should be determined by the PCR assay at the local laboratory at screening for this study

7. Patient is ambulatory.

8. Patient is willing and able to comply with the study drug regimen and all other study requirements.

9. The patient is willing and able to provide written informed consent to participate in the study.

Exclusion Criteria:

1. Patient has a history of hepatocellular carcinoma (HCC) or findings suggestive of possible HCC, such as suspicious foci on imaging studies or elevated serum alpha fetoprotein (AFP) levels. In patients with such findings, HCC should be ruled-out prior to randomizing the patient for the present study.

2. Patient previously received oral antiviral agent other than Lamivudine or Adefovir

3. Patient has received interferon or other immunomodulatory treatment for HBV infection within 12 months before screening for this study.

4. Patient has concomitant other chronic viral infection (HCV or HIV)

5. Patient has evidence of renal insufficiency defined as serum creatinine > 1.5 mg/dL

6. Patient has medical condition that requires use of systemic prednisolone or other immunosuppressive agent (including chemotherapeutic agent)

7. Patient is currently abusing alcohol or illicit drugs, or has a history of alcohol abuse or illicit substance abuse within the preceding two years.

8. Patient is pregnant or breastfeeding or willing to be pregnant

9. Patient has one or more additional known primary or secondary causes of liver disease, other than hepatitis B (e.g., alcoholism, autoimmune hepatitis, malignancy with hepatic involvement, hemochromatosis, alpha-1 antitrypsin deficiency, Wilson's Disease, other congenital or metabolic conditions affecting the liver, congestive heart failure or other severe cardiopulmonary disease, etc.).

10. A history of treated malignancy (other than hepatocellular carcinoma) is allowable if the patient's malignancy has been in complete remission, off chemotherapy and without additional surgical intervention, during the preceding three years.

11. Clinical signs of decompensated liver disease as indicated by any one of the following:

• serum bilirubin > 3 mg/dL

• prothrombin time > 6 seconds prolonged or INR >1.6

• serum albumin < 2.8 g/dL

• History of ascites, variceal hemorrhage, or hepatic encephalopathy

• Child-Pugh score =7

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Hepatitis
• Hepatitis A
• Hepatitis B
• Hepatitis B, Chronic
• Hepatitis, Chronic

Intervention

Drug:
• Adefovir
Adefovir dipivoxil (Hepsera) 10 mg/day orally for 104 weeks
• Entecavir
Entecavir 1 mg/day orally
• Lamivudine
Lamivudine (Zeffix) 100 mg/day orally

Locations

Country	Name	City	State
Korea, Republic of	Asan Medical Center	Seoul	the Meteropolis of Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Asan Medical Center

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Complete Virologic Response (CVR, Serum HBV DNA Undetectable by PCR or Less Than 60 IU/mL)		at week 52 from randomization	No
Secondary	Reduction in Serum HBV DNA Levels		at week 52 and at week 104 from randomization	Yes
Secondary	Genotypic Resistance to ADV or ETV		at week 52 and at week 104 from randomization	Yes
Secondary	Normalization of ALT Level		at week 52 and at week 104 from randomization	Yes
Secondary	Complete Virologic Response (CVR, Serum HBV DNA Undetectable by PCR or Less Than 60 IU/mL)		at week 104 from randomization	No